181 related articles for article (PubMed ID: 25198900)
41. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
42. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
Etienne MC; Chazal M; Laurent-Puig P; Magné N; Rosty C; Formento JL; Francoual M; Formento P; Renée N; Chamorey E; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
J Clin Oncol; 2002 Jun; 20(12):2832-43. PubMed ID: 12065560
[TBL] [Abstract][Full Text] [Related]
44. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
45. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
[TBL] [Abstract][Full Text] [Related]
46. Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Bai M; Goussia A; Samantas E; Galani E; Tsavdaridis D; Karina M; Papakostas P; Konstantara A; Fountzilas G
Anticancer Res; 2007; 27(4C):2973-83. PubMed ID: 17695481
[TBL] [Abstract][Full Text] [Related]
47. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
48. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
49. Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.
Bendardaf R; Lamlum H; Elzagheid A; Ristamäki R; Pyrhönen S
Oncol Rep; 2005 Sep; 14(3):657-62. PubMed ID: 16077970
[TBL] [Abstract][Full Text] [Related]
50. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
Li S; Zhu L; Yao L; Xia L; Pan L
BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
[TBL] [Abstract][Full Text] [Related]
51. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
[TBL] [Abstract][Full Text] [Related]
52. Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.
Kline CL; Sheikh HS; Scicchitano A; Gingrich R; Beachler C; Finnberg NK; Liao J; Sivik J; El-Deiry WS
Cancer Biol Ther; 2011 Oct; 12(7):557-68. PubMed ID: 21931273
[TBL] [Abstract][Full Text] [Related]
53. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Ikeguchi M; Arai Y; Maeta Y; Ashida K; Katano K; Wakatsuki T
Surg Today; 2011 Sep; 41(9):1196-9. PubMed ID: 21874414
[TBL] [Abstract][Full Text] [Related]
54. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial.
Leichman L; Lenz HJ; Leichman CG; Groshen S; Danenberg K; Baranda J; Spears CP; Boswell W; Silberman H; Ortega A
Eur J Cancer; 1995; 31A(7-8):1306-10. PubMed ID: 7577041
[TBL] [Abstract][Full Text] [Related]
55. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin.
Peters GJ; van Groeningen CJ; van der Wilt CL; Meijer S; Smid K; Laurensse E; Pinedo HM
Semin Oncol; 1992 Apr; 19(2 Suppl 3):26-35. PubMed ID: 1557655
[TBL] [Abstract][Full Text] [Related]
56. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
[TBL] [Abstract][Full Text] [Related]
57. Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis.
Vallböhmer D; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
Int J Oncol; 2006 Feb; 28(2):527-33. PubMed ID: 16391809
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.
Galimberti S; Nagy B; Benedetti E; Pacini S; Brizzi S; Caracciolo F; Papineschi F; Ciabatti E; Guerrini F; Fazzi R; Canestraro M; Petrini M
Leuk Lymphoma; 2007 Aug; 48(8):1502-9. PubMed ID: 17701580
[TBL] [Abstract][Full Text] [Related]
59. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
Sotelo MJ; García-Paredes B; Aguado C; Sastre J; Díaz-Rubio E
World J Gastroenterol; 2014 Apr; 20(15):4208-19. PubMed ID: 24764659
[TBL] [Abstract][Full Text] [Related]
60. Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.
Nielsen DL; Palshof JA; Brünner N; Stenvang J; Viuff BM
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28880238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]